HCB-301

The purpose of this trial is to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HCB301 IV infusion in subjects aged 18 years and above with advanced solid tumors and relapsed and refractory classical Hodgkin's lymphoma. Primary objective: To evaluate the safety and tolerability of HCB301; to confirm the MTD and RDE (recommended dose for extension phase). Secondary objective: To explore the PK characteristics of subjects receiving single and repeated administration of HCB301 at different dose levels; to evaluate the initial anti-tumor activity of repeated doses of HCB301 on subjects and the duration of response. Pharmacodynamic objective: To verify the dose-response relationship of HCB301 efficacy and safety variables; to verify potential predictive biomarkers of HCB301 response/clinical outcomes.